A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors

被引：0
|
作者：
Jonathan Metts
Brittany Harrington
Emad Salman
Scott M. Bradfield
Jennifer Flanary
Maua Mosha
Ernest Amankwah
Stacie Stapleton
机构：
[1] Johns Hopkins All Children’s Hospital,Cancer and Blood Disorders Institute
[2] Hospital Medicine,Division of Pediatric Hematology/Oncology
[3] MyMichigan Health,Data Coordinating Center for Pediatric Multicenter Studies
[4] Golisano Children’s Hospital of Southwest Florida,Department of Oncology
[5] Nemours Children’s Health,undefined
[6] Institute for Clinical and Translational Research,undefined
[7] Johns Hopkins All Children’s Hospital,undefined
[8] Johns Hopkins University School of Medicine,undefined
来源：
Child's Nervous System | 2022年 / 38卷
关键词：
Phase I; Pediatric; Brain tumor; Irinotecan; Temozolomide; Bevacizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 928
页数：9
相关论文
共 50 条
  • [21] A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
    Venkatramani, Rajkumar
    Malogolowkin, Marcio
    Davidson, Tom B.
    May, William
    Sposto, Richard
    Mascarenhas, Leo
    PLOS ONE, 2013, 8 (07):
  • [22] Efficacy and safety of bevacizumab, irinotecan, and temozolomide combination for relapsed or refractory pediatric central nervous system embryonal tumor: a single-institution study
    Shiba, Yoshiki
    Motomura, Kazuya
    Taniguchi, Rieko
    Kurimoto, Michihiro
    Mizutani, Kosuke
    Ohka, Fumiharu
    Aoki, Kosuke
    Ito, Eiji
    Nishikawa, Tomohide
    Yamaguchi, Junya
    Kibe, Yuji
    Shimizu, Hiroki
    Maeda, Sachi
    Nakashima, Takuma
    Suzuki, Hiromichi
    Muramatsu, Hideki
    Takahashi, Yoshiyuki
    Saito, Ryuta
    JOURNAL OF NEUROSURGERY-PEDIATRICS, 2023, 31 (06) : 624 - 632
  • [23] Bevacizumab and Irinotecan in the Treatment of Children With Recurrent/Refractory Medulloblastoma
    Aguilera, Dolly G.
    Goldman, Steward
    Fangusaro, Jason
    PEDIATRIC BLOOD & CANCER, 2011, 56 (03) : 491 - 494
  • [24] Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study
    Bagatell, R.
    Wagner, L. M.
    Cohn, S. L.
    Maris, J. M.
    Reynolds, C. P.
    Stewart, C. F.
    Voss, S. D.
    Gelfand, M.
    Kretschmar, C. S.
    London, W. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] SALVAGE CHEMOTHERAPY WITH BEVACIZUMAB-IRINOTECAN ASSOCIATION IN RECURRENT/REFRACTORY BRAIN TUMORS IN CHILDREN
    Schiavetti, A.
    Varrasso, G.
    Reale, G.
    De Grazia, A.
    Ferrara, E.
    Paiano, M.
    Clerico, A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S286 - S286
  • [26] Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors
    Carlos Rodriguez-Galindo
    Kristine R. Crews
    Clinton F. Stewart
    Wayne Furman
    J. Carl Panetta
    Najat C. Daw
    Alvida Cain
    Ming Tan
    Peter H. Houghton
    Victor M. Santana
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 15 - 24
  • [27] Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors
    Rodriguez-Galindo, C
    Crews, KR
    Stewart, CF
    Furman, W
    Panetta, JC
    Daw, NC
    Cain, A
    Tan, M
    Houghton, PH
    Santana, VM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 15 - 24
  • [28] Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study
    Modak, Shakeel
    Kushner, Brian H.
    Basu, Ellen
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (08)
  • [29] Phase II single-arm study of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma
    Grill, J.
    Perek, D.
    Sanchez de Toledo-Codina, J.
    Madero, L.
    Estlin, E.
    Canete, A.
    Icher, C.
    Breazna, A.
    Geoerger, B.
    Cisar, L.
    Hargrave, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
    Federico, Sara M.
    Pappo, Alberto S.
    Sahr, Natasha
    Sykes, April
    Campagne, Olivia
    Stewart, Clinton F.
    Clay, Michael R.
    Bahrami, Armita
    McCarville, Mary B.
    Kaste, Sue C.
    Santana, Victor M.
    Helmig, Sara
    Gartrell, Jessica
    Shelat, Anang
    Brennan, Rachel C.
    Hawkins, Dana
    Godwin, Kimberly
    Bishop, Michael W.
    Furman, Wayne L.
    Stewart, Elizabeth
    EUROPEAN JOURNAL OF CANCER, 2020, 137 : 204 - 213
12345